Approval of the use of a new drug on the NHS to treat those with a chronic kidney disease has been hailed as a "huge step forward". Dr Stewart Lambie, a consultant in renal and general medicine at ...

has granted full approval to Filspari ® (sparsentan) to slow kidney function decline in adults with primary immunoglobulin A (IgA) nephropathy who are at risk for disease progression. Filspari ...

There are various ways you can keep your kidneys healthy, from staying well hydrated and exercising regularly to maintaining ...

The regulator’s decision expands the drug’s indication to cover all patients who are at risk of disease progression The US Food and Drug Administration (FDA) has granted full approval to Travere ...

setting up a possible approval in September. CREDENCE found that Invokana was able to reduce the risk of end-stage kidney disease, the doubling of kidney health marker serum creatinine ...

From alcoholism to Parkinson’s, scientists are studying the mechanisms behind the broad clinical potential of weight-loss ...

Ardelyx Inc. on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney disease. The biopharma company said late Tuesday that the U.S ...

A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full FDA approval, strengthening the product’s case to compete against two other ...

Travere Therapeutics stock surged Friday after the biotech company snagged full Food and Drug Administration approval for its kidney disease treatment, Filspari. Please watch the video at ...